The Company is a pharmaceutical Company developing therapies for the treatment of chronic diseases and conditions with its proprietary drug formulations and delivery platform technologies.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
DRRX is going to be a winner in the short and long term. I have been following this stock for the last year or so and feel that it is at a point where it's pipeline is ripe for one of it's partners, namely KING, to come and make a buyout. I don't see it reaching double digits but I do see it as an easy $8.00 buy out candidate over the next year. I already own a fair amount of shares and continue to buy in the dips. However, if it were not bought out I would expect to see it in the double digits by this time next year. I just don't think it will get that far without someone making an offer...